MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
MeiraGTx Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$9.45+0.17 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $886.46M
- P/E (TTM)
- 13.3
- Dividend yield
- –
MeiraGTx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Market Cap | $907.61M | $164.85M |
| Enterprise Value | $864.65M | $87.06M |
| PE Ratio | 13.31 | 19.63 |
| PS Ratio | 2.28 | 3.60 |
| P/FCF Ratio | 86.71 | 17.44 |
| P/OCF Ratio | 66.30 | 13.32 |
Enterprise value
| Measure | MeiraGTx | Industry median |
|---|---|---|
| EV / Sales | 2.18 | 2.43 |
| EV / EBITDA | 4.41 | 14.69 |
| EV / EBIT | 4.70 | 18.47 |
| EV / FCF | 82.61 | 20.97 |
Income (trailing twelve months)
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Revenue | $397.50M | $57.94M |
| Operating Income | $184.03M | -$21.44M |
| Net Income | $78.98M | -$22.46M |
| EBITDA | $196.13M | -$16.91M |
| EPS (Diluted) | $0.71 | -$0.83 |
Margins
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Operating Margin | 46.3% | -44.5% |
| Profit Margin | 19.9% | -39.2% |
| EBITDA Margin | 49.3% | -31.3% |
| FCF Margin | 2.63% | -8.85% |
Returns
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2668.3% | -53.1% |
| Return on Assets (ROA) | 26.5% | -41.0% |
| Return on Invested Capital (ROIC) | 343.6% | -32.0% |
| Return on Capital Employed (ROCE) | 54.4% | -37.8% |
Growth
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 948.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 72.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 39.2% | 6.42% |
Balance sheet
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $143.17M | $62.42M |
| Total Debt | $100.00M | $120.13M |
| Net Cash (Debt) | $43.17M | $15.68M |
| Net Cash Per Share | $0.45 | $0.66 |
| Working Capital | $160.25M | $75.77M |
Financial position
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Current Ratio | 3.76 | 3.30 |
| Quick Ratio | 2.46 | 2.39 |
| Debt / EBITDA | 0.51 | 3.35 |
| Debt / FCF | 9.55 | 5.05 |
| Net Debt / EBITDA | -0.22 | 2.22 |
| Interest Coverage | 14.75 | -7.12 |
Cash flow (trailing twelve months)
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Operating Cash Flow | $13.69M | -$12.35M |
| Capital Expenditures | -$3.22M | -$1.06M |
| Free Cash Flow | $10.47M | -$20.28M |
| FCF Per Share | $0.11 | -$0.42 |
Efficiency
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Asset Turnover | 1.34 | 0.38 |
| Revenue Per Employee | $986.36K | $398.96K |
| Profits Per Employee | $195.99K | -$703.34K |
| Employee Count | 403 | 74 |
Dividends and yields
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Earnings Yield | 8.70% | -22.7% |
| FCF Yield | 1.15% | -9.07% |
| Buyback Yield | -14.7% | -0.73% |
| Shareholder Yield | -14.7% | 0.00% |
Shares
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Shares Outstanding | 96,043,000 | 58,179,650 |
| Shares Change (YoY) | 8.63% | 11.1% |
| Shares Change (QoQ) | 15.6% | 0.54% |
| Float | 62,153,200 | 49,173,100 |
| Shares Held by Insiders | 35.3% | 11.6% |
| Shares Held by Institutions | 82.5% | 59.4% |
Taxes
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Income Tax | $2.36M | $91.50K |
Scores
| Measure | MeiraGTx | Industry median |
|---|---|---|
| Altman Z-Score | 3.56 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from MeiraGTx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.